Company Overview and News
October 18, 2018: Here are four stocks trading with heavy volume among 278 equities making new 52-week lows in Thursday’s session. On the NYSE decliners led advancers by about 3.25 to 1, and on the Nasdaq, decliners led advancers by about 3.24 to 1.
F JCP FCX GM
Dividend growth stocks have taken it on the chin in October. That’s especially true of S&P 500 tech sector stocks. Only consumer discretionary and materials stocks have done worse over the same period.
HBANN HBANO F HBANP CIB MC HMC HBAN APAM LULU VZ GM
2018-10-16 investorplace - 1
The stock indexes in China have been bright green since February, which is a bad thing. In China, a down day is shown as green on Chinese tickers and red is positive. The green has only gotten worse since U.S. exchanges went into the “red” at the beginning of October. Normally, it isn’t a good idea to equate a stock index with the economy. They are usually correlated, but not always.
2018-10-16 investorplace - 1
As International Business Machines (NYSE:IBM) prepares to lead off another edition of tech earnings after trading closes Oct. 16, traders will be looking to the top line of revenue more closely than the bottom line of earnings.
IBM F AMZN MSFT NYTAB
Ford Motor Co. (NYSE: F) has released a new car in China. It says the new vehicle is aimed at China’s middle market, which is growing. Ford’s fortunes in China are so badly damaged that it will need enough models to fill a showroom to hope for a turnaround.
Microsoft Corp co-founder Paul Allen, the man who persuaded school-friend Bill Gates to drop out of Harvard to start what became the world’s biggest software company, died on Monday at the age of 65, his family said.
F MSFT JGLMY
U.S. stock futures are trading slightly lower as investors return from the weekend. The calm open is a welcome development after the back-breaking volatility of last week. Bulls are hoping to build upon Friday’s rebound attempts.
BAC F C JPM
2018-10-15 investorplace - 2
Do you think General Electric (NYSE:GE) should have fired its CEO? GE’s board did, letting John Flannery go after just 16 months in the job. On Flannery’s watch, GE stock lost 52% of its value and was booted off the Dow Jones after more than 100 years on the index.
IBM GE F GEC UL AAL SHLD NWL KHC GNE MS GM DHR IVZ
Sears Holdings Corp filed for Chapter 11 bankruptcy on Monday with a plan to close 142 more stores, throwing into doubt the future of the century-old retailer that once dominated U.S. malls but has withered in the age of internet shopping.
CCF SHLD GS GLSSP BOE JBK F GSC TFG MA GSJ JPM SNE SHLDW HRS GJS BA
What the title of today's blog doesn't tell you is that valuation is a slippery slope. Some of the seemingly cheapest stocks in the S&P 500 are not really attractive values but more "value-traps," which, like the Sirens of Greek mythology fame, lure investors in, only to see themselves dashed on the rocks. Ford (NYSE:F), General Motors (NYSE:GM) and Bed Bath (NASDAQ:BBBY) all come to mind. All very cheap on a valuation basis, all adept at destroying investor capital.
F GM BBBY
China is the world’s largest car market and almost all car industry experts believe that no global manufacturer can flourish without strong sales in the country which has a population of 1.4 billion people, well over four times the number of people in the U.S. Ford Motor Co.’s (NYSE: F) sales fell 43% in China in September, a blow to the already reeling company and a threat to the tenure of its embattled CEO James Patrick “Jim” Hackett.
2018-10-13 247wallst - 1
October 12, 2018: Here are four stocks trading with heavy volume among 465 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.35 to 1, and on the Nasdaq, advancers led decliners by about 1.44 to 1.
F NLY GM MS
2018-10-12 247wallst - 1
Ford Motor Co. (NYSE: F) is having a very bad year in China. Sales fell 43% year over year in September and are down 30% for the first nine months of the year. The only positive news is that every automaker is struggling too.
October 11, 2018: Here are four stocks trading with heavy volume among 513 equities making new 52-week lows in Thursday’s session. On the NYSE decliners led advancers by about 3.5 to 1, and on the Nasdaq, decliners led advancers by about 2.31 to 1.
BABA F AMAT SNAP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to F / Ford Motor Co. on message board site Silicon Investor.
as of ET